Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Outlook
  • Published:

The evolving landscape of RAS-targeted therapies

Nature Cancer volume 6, pages 1913–1915 (2025) Cite this article

Subjects

The initial discovery of an inhibitor of KRAS G12C revolutionized the KRAS field. Since then, more-potent G12C-specific inhibitors, newer allele-specific inhibitors and combinations based on KRAS targeting have advanced through clinical trials, which has led to approval by the US Food and Drug Administration of the first KRAS–EGFR inhibition combinations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Prior, I. A., Hood, F. E. & Hartley, J. L. Cancer Res. 80, 2969–2974 (2020).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Cox, A. D. & Der, C. J. Genes Dev. https://doi.org/10.1101/gad.352081.124 (2024).

    Article  Google Scholar 

  3. Zhang, Z., Morstein, J., Ecker, A. K., Guiley, K. Z. & Shokat, K. M. J. Am. Chem. Soc. 144, 15916–15921 (2022).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Zhang, Z., Guiley, K. Z. & Shokat, K. M. Nat. Chem. Biol. 18, 1177–1183 (2022).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Nilewski, C. et al. ACS Med. Chem. Lett. 15, 21–28 (2024).

    Article  PubMed  CAS  Google Scholar 

  6. Popow, J. et al. Science 385, 1338–1347 (2024).

    Article  PubMed  CAS  Google Scholar 

  7. Cho, B. C. et al. Nat. Med. 31, 2768–2777 (2025).

    Article  PubMed  CAS  Google Scholar 

  8. Isermann, T., Sers, C., Der, C. J. & Papke, B. Trends Cancer 11, 91–116 (2025).

    Article  PubMed  CAS  Google Scholar 

  9. Meng, X. et al. Cancer Res. 85, CT138–CT138 (2025).

    Article  Google Scholar 

  10. Barlesi, F. et al. Lancet 406, 615–626 (2025).

    Article  PubMed  CAS  Google Scholar 

  11. Sacher, A. G. et al. J. Clin. Oncol. https://doi.org/10.1200/JCO-25-00040 (2025).

    Article  PubMed  Google Scholar 

  12. Lugowska, I. A. et al. J. Clin. Oncol. 43, 3508–3508 (2025).

    Article  Google Scholar 

  13. Wolpin, B. M. et al. J. Clin. Oncol. 43, (2025).

  14. Yaeger, R. et al. N. Engl. J. Med. 388, 44–54 (2023).

    Article  PubMed  CAS  Google Scholar 

  15. Fakih, M. G. et al. N. Engl. J. Med. 389, 2125–2139 (2023).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Genetics and Epigenetics Program, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Sandra Misale

Authors
  1. Sandra Misale
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Sandra Misale.

Ethics declarations

Competing interests

S.M. is a founder and scientific advisor of Thera65, is a consultant to Merck, and receives research funding from AstraZeneca.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Misale, S. The evolving landscape of RAS-targeted therapies. Nat Cancer 6, 1913–1915 (2025). https://doi.org/10.1038/s43018-025-01077-z

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s43018-025-01077-z

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research